Moderna, Inc. Stock Rises 44.2% in Six Months as Melanoma Trial Hits Targets

Moderna, Inc. stock shows a bullish daily structure, yet shorter-term charts flash caution. The gap between the broader trend and the intraday tape defines the core story for MRNA right now. It sets up a classic trend-versus-pullback debate.

Key takeaways

• MRNA closed at $62.96 on August 18, holding above all three key daily EMAs in a textbook bullish stack.
• Daily RSI14 at 55.04 and a positive MACD histogram of 0.92 confirm intact uptrend momentum with no overbought signal.
• Hourly momentum is cooling: RSI14 slipped to 46.62 and MACD turned negative, though the daily trend remains firmly intact.
• Moderna and Merck’s Phase 3 melanoma trial met both recurrence-free and distant metastasis-free survival endpoints.
• MRNA shares climbed 44.2% in the prior six months, with elevated volatility (ATR14 of 3.76) still a defining feature.

Daily Chart: EMA Stack Confirms Bullish Structure

The daily chart maintains a clear bullish posture for Moderna, Inc. stock. Price holds above all three key moving averages, and constructive momentum readings support further upside.

… Continue reading the full article at the original source below.